Experimental pill targets Hard-to-Treat cancers with genetic flaw
NCT ID NCT05275478
First seen Nov 15, 2025 · Last updated Apr 28, 2026 · Updated 17 times
Summary
This study tested an experimental drug called TNG908 in people with advanced solid tumors that lack a gene called MTAP. The drug works by blocking a protein that these cancer cells need to grow. The trial aimed to find the safest dose and see if the drug could shrink tumors, but it was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carle Cancer Center
Urbana, Illinois, 61801, United States
-
Centre Léon Bérard
Lyon, 69373, France
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
EDOG Institut de Cancerologie de l'Ouest
Saint-Herblain, 44805, France
-
Florida Cancer Specialists & Research Institute
Lake Mary, Florida, 32746, United States
-
Grand Valley Oncology
Grand Junction, Colorado, 81505, United States
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut Oncopole Claudius Regaud
Toulouse, 31059, France
-
Institute Gustav Roussy
Villejuif, 94805, France
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10022, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
Sarah Cannon Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.